DUBLIN, Aug. 25, 2021 /PRNewswire/ -- The "Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
Research and Markets Logo
The global multiple myeloma drugs market exhibited strong growth during 2015-2020. Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells. Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents. These pharmaceutical drugs aid in promoting bone healing, prevent hypercalcemia, bone fracture, spinal cord compression and anemia, while minimizing the need for chemotherapy. The chemotherapeutic agents include various anthracycline antibiotics and alkylating agents, such as melphalan, doxorubicin, vincristine and liposomal doxorubicin. The targeted therapy drugs include proteasome inhibitor, such as bortezomib, and various other compounds, including dexamethasone, prednisone and thalidomide.
Significant developments in the healthcare sector, along with the increasing prevalence of hematological cancer, is one of the key factors driving the growth of the market. Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves drugs that modulate the immune system and aid in enhancing the efficiency of chemotherapies, radiation therapies, stem cell transplants and platelet transfusion. Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the body's immune system to identify and attack the myeloma cells, is also providing a boost to the market growth.
Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor. These medicines are used to facilitate the delivery of macromolecular agents into the bone marrow and catalyze antitumor responses. Other factors, including the rising healthcare expenditures and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further. Looking forward, the publisher expects the global multiple myeloma drugs market to grow at a CAGR of around 10% during the forecast period (2021-2026).
Story continues
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Genzyme Corporation (Sanofi-Aventis), Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Pharma Mar S.A., Takeda Pharmaceutical Company Limited., Teva Pharmaceutical Industries Ltd., etc.
Key Questions Answered in This Report:
How has the global multiple myeloma drugs market performed so far and how will it perform in the coming years?
What are the key regional markets?
What has been the impact of COVID-19 on the global multiple myeloma drugs market?
What is the breakup of the market based on the therapy?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the end-user?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global multiple myeloma drugs market and who are the key players?
What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction4.1 Overview4.2 Key Industry Trends
5 Global Multiple Myeloma Drugs Market5.1 Market Overview5.2 Market Performance5.3 Impact of COVID-195.4 Market Forecast
6 Market Breakup by Therapy6.1 Targeted Therapy6.1.1 Market Trends6.1.2 Market Forecast6.2 Biologic Therapy6.2.1 Market Trends6.2.2 Market Forecast6.3 Chemotherapy6.3.1 Market Trends6.3.2 Market Forecast6.4 Others6.4.1 Market Trends6.4.2 Market Forecast
7 Market Breakup by Drug Type7.1 Immunomodulatory Drugs7.1.1 Market Trends7.1.2 Market Forecast7.2 Proteasome Inhibitors7.2.1 Market Trends7.2.2 Market Forecast7.3 Histone Deacetylase Inhibitors7.3.1 Market Trends7.3.2 Market Forecast7.4 Monoclonal Antibody Drugs7.4.1 Market Trends7.4.2 Market Forecast7.5 Steroids7.5.1 Market Trends7.5.2 Market Forecast7.6 Others7.6.1 Market Trends7.6.2 Market Forecast
8 Market Breakup by End-User8.1 Men8.1.1 Market Trends8.1.2 Market Forecast8.2 Women8.2.1 Market Trends8.2.2 Market Forecast
9 Market Breakup by Distribution Channel9.1 Hospital Pharmacies9.1.1 Market Trends9.1.2 Market Forecast9.2 Retail Pharmacies9.2.1 Market Trends9.2.2 Market Forecast9.3 Online Pharmacies9.3.1 Market Trends9.3.2 Market Forecast9.4 Others9.4.1 Market Trends9.4.2 Market Forecast
10 Market Breakup by Region10.1 North America10.1.1 United States10.1.1.1 Market Trends10.1.1.2 Market Forecast10.1.2 Canada10.1.2.1 Market Trends10.1.2.2 Market Forecast10.2 Asia Pacific10.2.1 China10.2.1.1 Market Trends10.2.1.2 Market Forecast10.2.2 Japan10.2.2.1 Market Trends10.2.2.2 Market Forecast10.2.3 India10.2.3.1 Market Trends10.2.3.2 Market Forecast10.2.4 South Korea10.2.4.1 Market Trends10.2.4.2 Market Forecast10.2.5 Australia10.2.5.1 Market Trends10.2.5.2 Market Forecast10.2.6 Indonesia10.2.6.1 Market Trends10.2.6.2 Market Forecast10.2.7 Others10.2.7.1 Market Trends10.2.7.2 Market Forecast10.3 Europe10.3.1 Germany10.3.1.1 Market Trends10.3.1.2 Market Forecast10.3.2 France10.3.2.1 Market Trends10.3.2.2 Market Forecast10.3.3 United Kingdom10.3.3.1 Market Trends10.3.3.2 Market Forecast10.3.4 Italy10.3.4.1 Market Trends10.3.4.2 Market Forecast10.3.5 Spain10.3.5.1 Market Trends10.3.5.2 Market Forecast10.3.6 Russia10.3.6.1 Market Trends10.3.6.2 Market Forecast10.3.7 Others10.3.7.1 Market Trends10.3.7.2 Market Forecast10.4 Latin America10.4.1 Brazil10.4.1.1 Market Trends10.4.1.2 Market Forecast10.4.2 Mexico10.4.2.1 Market Trends10.4.2.2 Market Forecast10.4.3 Others10.4.3.1 Market Trends10.4.3.2 Market Forecast10.5 Middle East and Africa10.5.1 Market Trends10.5.2 Market Breakup by Country10.5.3 Market Forecast
11 SWOT Analysis11.1 Overview11.2 Strengths11.3 Weaknesses11.4 Opportunities11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis13.1 Overview13.2 Bargaining Power of Buyers13.3 Bargaining Power of Suppliers13.4 Degree of Competition13.5 Threat of New Entrants13.6 Threat of Substitutes
14 Price Indicators
15 Competitive Landscape15.1 Market Structure15.2 Key Players15.3 Profiles of Key Players15.3.1 Amgen Inc.15.3.1.1 Company Overview15.3.1.2 Product Portfolio15.3.1.3 Financials15.3.1.4 SWOT Analysis15.3.2 Bristol-Myers Squibb Company15.3.2.1 Company Overview15.3.2.2 Product Portfolio15.3.2.3 Financials15.3.2.4 SWOT Analysis15.3.3 DAIICHI SANKYO COMPANY15.3.3.1 Company Overview15.3.3.2 Product Portfolio15.3.3.3 Financials15.3.3.4 SWOT Analysis15.3.4 Genzyme Corporation (Sanofi-Aventis)15.3.4.1 Company Overview15.3.4.2 Product Portfolio15.3.4.3 SWOT Analysis15.3.5 Johnson & Johnson Services Inc.15.3.5.1 Company Overview15.3.5.2 Product Portfolio15.3.5.3 Financials15.3.5.4 SWOT Analysis15.3.6 Merck & Co. Inc.15.3.6.1 Company Overview15.3.6.2 Product Portfolio15.3.6.3 Financials15.3.6.4 SWOT Analysis15.3.7 Novartis AG15.3.7.1 Company Overview15.3.7.2 Product Portfolio15.3.7.3 Financials15.3.7.4 SWOT Analysis15.3.8 Pfizer Inc.15.3.8.1 Company Overview15.3.8.2 Product Portfolio15.3.8.3 Financials15.3.8.4 SWOT Analysis15.3.9 Pharma Mar S.A.15.3.9.1 Company Overview15.3.9.2 Product Portfolio15.3.9.3 Financials15.3.10 Takeda Pharmaceutical Company Limited.15.3.10.1 Company Overview15.3.10.2 Product Portfolio15.3.10.3 Financials15.3.10.4 SWOT Analysis15.3.11 Teva Pharmaceutical Industries Ltd.15.3.11.1 Company Overview15.3.11.2 Product Portfolio15.3.11.3 Financials15.3.11.4 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/9ll3jo
Media Contact: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716
Cision
View original content:https://www.prnewswire.com/news-releases/outlook-on-the-multiple-myeloma-drugs-global-market-to-2026---by-therapy-drug-type-end-user-distribution-channel-and-region-301362845.html
SOURCE Research and Markets
Originally posted here:
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 6th, 2024
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
Recent Comments